US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
CA2281224A1
(en)
|
1997-02-15 |
1998-08-20 |
Proscript, Inc. |
Treatment of infarcts through inhibition of nf-kappab
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
JP2001517631A
(ja)
*
|
1997-09-25 |
2001-10-09 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したNF−κBの活性化に干渉する剤
|
ES2285785T3
(es)
*
|
1997-09-29 |
2007-11-16 |
Point Therapeutics, Inc. |
Estimulacion de celulas hematopoyeticas in vitro.
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
*
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(de)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalente Proteasome Inhibitore
|
AU762373B2
(en)
*
|
1998-10-20 |
2003-06-26 |
Millennium Pharmaceuticals, Inc. |
Method for monitoring proteasome inhibitor drug action
|
US6492333B1
(en)
*
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
AU2001287399A1
(en)
*
|
2000-08-16 |
2002-02-25 |
University Of Alberta |
Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
JP2004510826A
(ja)
*
|
2000-10-12 |
2004-04-08 |
ヴィローミクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ウイルス感染の治療剤
|
DK1355910T3
(da)
*
|
2001-01-25 |
2011-06-27 |
Us Of America Represented By The Secretary Dept Of Health And Human Services |
Formulering af borsyreforbindelser
|
WO2002094311A1
(en)
|
2001-05-21 |
2002-11-28 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
CN100415770C
(zh)
*
|
2001-05-30 |
2008-09-03 |
诺瓦提斯公司 |
2-{[n-(2-氨基-3-(杂芳基或芳基)丙酰基)-氨基酰基]-氨基}-烷基硼酸衍生物
|
WO2003033506A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
|
WO2003033507A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
|
US7524883B2
(en)
|
2002-01-08 |
2009-04-28 |
Eisai R&D Management Co., Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
AU2003218232A1
(en)
*
|
2002-03-12 |
2003-09-29 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
KR20040093692A
(ko)
*
|
2002-03-13 |
2004-11-08 |
얀센 파마슈티카 엔.브이. |
히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체
|
BR0307599A
(pt)
|
2002-03-13 |
2005-02-01 |
Janssen Pharmaceutica Nv |
Derivados de sulfonilamino como inibidores de histona deacetilase
|
DE60326436D1
(en)
|
2002-03-13 |
2009-04-16 |
Janssen Pharmaceutica Nv |
Aminoderivate als histone-deacetylase-inhibitoren
|
NZ534831A
(en)
|
2002-03-13 |
2007-01-26 |
Janssen Pharmaceutica Nv |
Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity
|
DE10316735A1
(de)
*
|
2002-04-05 |
2003-11-20 |
Viromics Gmbh |
Mittel zur Behandlung von Flaviviridae-Infektionen
|
WO2003106384A2
(en)
*
|
2002-06-01 |
2003-12-24 |
Johns Hopkins University |
Novel boronic chalcone derivatives and uses thereof
|
WO2004004658A2
(en)
*
|
2002-07-09 |
2004-01-15 |
Point Therapeutics, Inc. |
Methods and compositions relating to isoleucine boroproline compounds
|
WO2004016253A1
(en)
*
|
2002-08-14 |
2004-02-26 |
Janssen Pharmaceutica N.V. |
Use of nf-kappa b inhibitors for the treatment of mastitis
|
US7371729B2
(en)
*
|
2002-09-09 |
2008-05-13 |
Trigen Limited |
Boronic acid salts useful in parenteral formulations
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
MXPA05002661A
(es)
*
|
2002-09-09 |
2005-08-19 |
Trigen Ltd |
Sales de acido boronico y su uso en el tratamiento de trombosis.
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
KR20050057175A
(ko)
*
|
2002-09-20 |
2005-06-16 |
알콘, 인코퍼레이티드 |
안구건조증 치료용 사이토카인 합성 저해제의 용도
|
ES2542328T3
(es)
|
2002-12-06 |
2015-08-04 |
Millennium Pharmaceuticals, Inc. |
Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
WO2005007211A2
(en)
*
|
2003-07-03 |
2005-01-27 |
Medtronic Vascular Inc. |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
SG148161A1
(en)
|
2003-11-05 |
2008-12-31 |
Palingen Inc |
Enhanced b cell cytotoxicity of cdim binding antibody
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
KR20130016435A
(ko)
*
|
2004-02-23 |
2013-02-14 |
트러스티즈 오브 터프츠 칼리지 |
디펩티딜펩티다아제 ⅳ의 억제제
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
PT1756121E
(pt)
*
|
2004-03-30 |
2011-11-30 |
Millennium Pharm Inc |
Síntese de compostos de ácido e de éster borónico
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
CA2562411A1
(en)
|
2004-04-15 |
2005-11-10 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
EP2564834A3
(de)
|
2004-05-10 |
2013-08-21 |
Onyx Therapeutics, Inc. |
Verbindungen zur Proteasomenzyminhibition
|
EP1765313A2
(de)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen als immunstimulatoren
|
CA2574418A1
(en)
|
2004-07-23 |
2006-02-02 |
Susan Marie Royalty |
Peptidase inhibitors
|
PL1781639T3
(pl)
|
2004-07-28 |
2012-07-31 |
Janssen Pharmaceutica Nv |
Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
|
EP2100899A3
(de)
|
2004-10-20 |
2009-09-30 |
Proteolix, Inc. |
Verbindungen zur Enzyminhibition
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
JP2008519030A
(ja)
|
2004-11-05 |
2008-06-05 |
パリンゲン インコーポレーテッド |
抗体で誘導される細胞膜損傷
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
EP1845973B1
(de)
|
2005-01-21 |
2015-08-12 |
Astex Therapeutics Limited |
Pharmazeutische verbindungen
|
WO2006081371A2
(en)
*
|
2005-01-27 |
2006-08-03 |
Research Development Foundation |
Combination therapy with triterpenoid compounds and proteasome inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
KR101337068B1
(ko)
|
2005-02-16 |
2013-12-06 |
아나코르 파마슈티칼스 인코포레이티드 |
보론함유 소분자
|
WO2006099261A2
(en)
*
|
2005-03-11 |
2006-09-21 |
The University Of North Carolina At Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
CA2604424A1
(en)
*
|
2005-04-29 |
2006-11-09 |
Kosan Biosciences Incorporated |
Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
|
CA2605272C
(en)
|
2005-05-18 |
2013-12-10 |
Janssen Pharmaceutica N.V. |
Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
PL1888123T3
(pl)
*
|
2005-06-08 |
2013-06-28 |
Janssen Biotech Inc |
Terapia komórkowa chorób degeneracyjnych oka
|
EP1912664A2
(de)
*
|
2005-07-06 |
2008-04-23 |
Biodevelops Pharma Entwicklung GmbH |
Verwendung einer verbindung zur verstärkung der expression von membranproteinen auf der zelloberfläche
|
EP1752467A1
(de)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Krebszellen-, t-Zellen- und Keratinocyte-Proliferation-Inhibitoren
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
PL2623113T3
(pl)
*
|
2005-11-09 |
2018-05-30 |
Onyx Therapeutics, Inc. |
Związek do hamowania enzymu
|
EP1956908A2
(de)
*
|
2005-12-08 |
2008-08-20 |
Cytokinetics, Inc. |
Gewisse zusammensetzungen und behandlungsverfahren
|
JP2009526751A
(ja)
|
2005-12-30 |
2009-07-23 |
アナコール ファーマシューティカルズ,インコーポレイテッド |
ホウ素含有小分子
|
DK1981875T3
(da)
*
|
2006-01-19 |
2014-07-14 |
Janssen Pharmaceutica Nv |
Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
|
US8114876B2
(en)
*
|
2006-01-19 |
2012-02-14 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
DE602007001190D1
(de)
*
|
2006-01-19 |
2009-07-09 |
Janssen Pharmaceutica Nv |
Aminophenylderivate als neue inhibitoren von histondeacetylase
|
CN101370789B
(zh)
*
|
2006-01-19 |
2012-05-30 |
詹森药业有限公司 |
作为组蛋白脱乙酰酶抑制剂的吡啶和嘧啶衍生物
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
EP1988779B1
(de)
*
|
2006-02-16 |
2015-06-24 |
Anacor Pharmaceuticals, Inc. |
Kleine boronhaltige moleküle als entzündungshemmende wirkstoffe
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
*
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
BRPI0713309A2
(pt)
|
2006-06-19 |
2012-04-17 |
Proteolix Inc |
compostos para inibição de enzimas
|
JP5230625B2
(ja)
*
|
2006-09-15 |
2013-07-10 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
クラス−i特異的ヒストンデアセチラーゼ阻害剤とプロテアソーム阻害剤の組み合わせ
|
JP5185274B2
(ja)
*
|
2006-09-15 |
2013-04-17 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
プロテアソームインヒビターと組み合わせてクラスiおよびクラスiibヒストンデアセチラーゼに対する組み合わせ活性を持つヒストンデアセチラーゼインヒビター
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
CA2606634A1
(en)
*
|
2006-12-08 |
2008-06-08 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
*
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
EP2185693B1
(de)
|
2007-07-31 |
2019-07-03 |
Lifescan, Inc. |
Differenzierung menschlicher embryonaler stammzellen
|
PL2170396T3
(pl)
|
2007-08-03 |
2017-07-31 |
Summit (Oxford) Limited |
Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
KR20160040735A
(ko)
*
|
2007-08-06 |
2016-04-14 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
프로테아좀 억제제
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
EP2185159A4
(de)
*
|
2007-09-12 |
2012-02-08 |
Reddys Lab Ltd Dr |
Bortezomib und herstellungsverfahren dafür
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
MY166950A
(en)
|
2007-10-04 |
2018-07-25 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
US9062290B2
(en)
|
2007-11-27 |
2015-06-23 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
CN101952282A
(zh)
|
2007-12-20 |
2011-01-19 |
诺瓦提斯公司 |
用作pi 3激酶抑制剂的噻唑衍生物
|
MX2010009251A
(es)
|
2008-02-21 |
2010-11-25 |
Centocor Ortho Biotech Inc |
Metodos, placas de superficie modificada y composiciones para la fijacion, el cultivo y el desprendimiento celular.
|
US8039450B2
(en)
|
2008-03-06 |
2011-10-18 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-inflammatory agents
|
EP2285384A4
(de)
*
|
2008-05-12 |
2012-04-25 |
Anacor Pharmaceuticals Inc |
Borhaltige kleine moleküle
|
SI2318419T1
(sl)
*
|
2008-06-17 |
2015-07-31 |
Millennium Pharmaceuticals, Inc. |
Spojine boronat estra in njihovi farmacevtski sestavki
|
ES2697798T3
(es)
|
2008-06-30 |
2019-01-28 |
Janssen Biotech Inc |
Diferenciación de células madre pluripotentes
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
WO2010028005A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2010027975A1
(en)
*
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
WO2010045503A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EA024364B1
(ru)
|
2008-10-21 |
2016-09-30 |
Оникс Терапьютикс, Инк. |
Способ лечения множественной миеломы
|
CA2742268C
(en)
|
2008-10-31 |
2020-02-18 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
|
CN102333862B
(zh)
*
|
2008-10-31 |
2018-04-27 |
詹森生物科技公司 |
人胚胎干细胞向胰腺内分泌谱系的分化
|
CA2744227C
(en)
*
|
2008-11-20 |
2018-10-02 |
Centocor Ortho Biotech Inc. |
Methods and compositions for cell attachment and cultivation on planar substrates
|
AU2009316580B2
(en)
|
2008-11-20 |
2016-04-14 |
Janssen Biotech, Inc. |
Pluripotent stem cell culture on micro-carriers
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
AU2009335744A1
(en)
*
|
2008-12-17 |
2010-07-15 |
Anacor Pharmaceuticals, Inc. |
Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol
|
MX2011007192A
(es)
|
2009-01-09 |
2011-10-04 |
Sun Pharma Advanced Res Co Ltd |
Composicion farmaceutica.
|
EP2399129B1
(de)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
Verfahren zur diagnose bzw. prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma
|
JP5709766B2
(ja)
|
2009-03-12 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
WO2010111361A1
(en)
|
2009-03-24 |
2010-09-30 |
Janssen Pharmaceutica Nv |
Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor
|
CA2756072A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
MX2011012538A
(es)
*
|
2009-05-27 |
2012-02-08 |
Cephalon Inc |
Terapia de combinacion para el tratamiento del mieloma multiple.
|
EP2270019A1
(de)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
Neue synthetische Route zur Herstellung von alpha-Aminoborestern
|
CN101928329B
(zh)
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
JP2012530116A
(ja)
|
2009-06-19 |
2012-11-29 |
レツク・フアーマシユーテイカルズ・デー・デー |
脱ハロゲン化なしにハロゲノアルケンを水素化する方法
|
EP2280016A1
(de)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
Neue synthetische Route zur Herstellung von Alpha-Aminoborestern über substituierte Alylene
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
GB2485113B
(en)
|
2009-07-20 |
2016-12-28 |
Janssen Biotech Inc |
Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage
|
KR20170118969A
(ko)
|
2009-07-20 |
2017-10-25 |
얀센 바이오테크 인코포레이티드 |
인간 배아 줄기 세포의 분화
|
EP2456858B1
(de)
*
|
2009-07-20 |
2018-08-29 |
Janssen Biotech, Inc. |
Differenzierung menschlicher embryonischer stammzellen
|
US8343944B2
(en)
*
|
2009-07-28 |
2013-01-01 |
Anacor Pharmaceuticals, Inc. |
Trisubstituted boron-containing molecules
|
WO2011019618A1
(en)
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
US20120149663A1
(en)
|
2009-08-18 |
2012-06-14 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
WO2011022337A1
(en)
*
|
2009-08-19 |
2011-02-24 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
SG178986A1
(en)
|
2009-09-08 |
2012-04-27 |
Hoffmann La Roche |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(de)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
|
US20110189204A1
(en)
|
2009-10-01 |
2011-08-04 |
Roland De Coster |
Treatment of Disease with Proteasone Inhibitors
|
US9346834B2
(en)
|
2009-10-20 |
2016-05-24 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
US8461134B2
(en)
*
|
2009-11-11 |
2013-06-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
EP2516449A1
(de)
*
|
2009-12-22 |
2012-10-31 |
Cephalon, Inc. |
Proteasehemmer und verfahren zu ihrer herstellung, reinigung und verwendung
|
WO2011079017A2
(en)
|
2009-12-23 |
2011-06-30 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
PL2516626T3
(pl)
|
2009-12-23 |
2017-10-31 |
Janssen Biotech Inc |
Różnicowanie ludzkich zarodkowych komórek macierzystych
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011094450A1
(en)
|
2010-01-27 |
2011-08-04 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules
|
EP2542238B1
(de)
*
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Verbindungen zur immunproteasomhemmung
|
SG10201501503VA
(en)
*
|
2010-03-01 |
2015-04-29 |
Janssen Biotech Inc |
Methods for purifying cells derived from pluripotent stem cells
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
AU2011227083B2
(en)
*
|
2010-03-18 |
2013-07-18 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8623911B2
(en)
|
2010-03-19 |
2014-01-07 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
NZ602622A
(en)
|
2010-03-31 |
2015-01-30 |
Millennium Pharm Inc |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
BR112012025264A2
(pt)
|
2010-04-07 |
2019-09-24 |
Onyx Therapeutics Inc |
inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
JP5801378B2
(ja)
|
2010-04-19 |
2015-10-28 |
ニーキ ファーマ インコーポレイテッド |
プロテアソーム阻害剤およびガリウム錯体を用いた併用療法
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
RU2663339C1
(ru)
|
2010-05-12 |
2018-08-03 |
Янссен Байотек, Инк. |
Дифференцирование эмбриональных стволовых клеток человека
|
US20110300150A1
(en)
|
2010-05-18 |
2011-12-08 |
Scott Eliasof |
Compositions and methods for treatment of autoimmune and other disease
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
EP3372672A1
(de)
|
2010-08-31 |
2018-09-12 |
Janssen Biotech, Inc. |
Differenzierung menschlicher embryonischer stammzellen
|
EP2611910B1
(de)
|
2010-08-31 |
2018-01-17 |
Janssen Biotech, Inc. |
Differenzierung menschlicher embryonischer stammzellen
|
BR112013004614A2
(pt)
|
2010-08-31 |
2024-01-16 |
Janssen Biotech Inc |
Diferenciação de células-tronco pluripotentes
|
DK3251678T3
(da)
|
2010-09-07 |
2021-11-22 |
Anacor Pharmaceuticals Inc |
Benzoxaborolderivater til behandling af bakterieinfektioner
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
CA2813003A1
(en)
|
2010-10-05 |
2012-04-12 |
Fresenius Kabi Usa, Llc |
Bortezomib formulations stabilised with boric acid
|
WO2012048745A1
(en)
|
2010-10-14 |
2012-04-19 |
Synthon Bv |
Process for making bortezomib and intermediates for the process
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
WO2012135528A2
(en)
|
2011-03-29 |
2012-10-04 |
Texas Tech University System |
Galectin-3c combination therapy for human cancer
|
CN103502319B
(zh)
|
2011-03-31 |
2015-11-25 |
那野伽利阿株式会社 |
包含含有硼酸化合物的嵌段共聚物的医药组合物
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
WO2012177835A1
(en)
*
|
2011-06-22 |
2012-12-27 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
RU2600026C2
(ru)
|
2011-08-11 |
2016-10-20 |
Янссен Фармацевтика Нв |
Прогностические факторы для лечения рака
|
BR112014002845A2
(pt)
|
2011-08-19 |
2017-02-21 |
Glaxo Group Ltd |
composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
|
JP6207509B2
(ja)
|
2011-08-30 |
2017-10-04 |
トラスティーズ オブ タフツ カレッジ |
固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
JP6238900B2
(ja)
|
2011-10-28 |
2017-11-29 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
Nae阻害物質に対する応答のバイオマーカー
|
WO2013071142A1
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
CN104126017A
(zh)
|
2011-11-11 |
2014-10-29 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
CN104093768B
(zh)
|
2011-11-17 |
2016-09-21 |
国立大学法人东京大学 |
导入有苯基硼酸基的嵌段共聚物及其使用
|
JP6441080B2
(ja)
|
2011-12-22 |
2018-12-19 |
ヤンセン バイオテツク,インコーポレーテツド |
単一ホルモンのインスリン陽性細胞へのヒト胚性幹細胞の分化
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
WO2013110005A1
(en)
|
2012-01-18 |
2013-07-25 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
CA2862492A1
(en)
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
US10085987B2
(en)
|
2012-01-27 |
2018-10-02 |
Thomas Jefferson University |
MCT protein inhibitor-related prognostic and therapeutic methods
|
TWI606064B
(zh)
|
2012-02-08 |
2017-11-21 |
Igm生物科技公司 |
細胞死亡誘導分子(cdim)結合蛋白類及彼等之用途
|
EP2819673B1
(de)
|
2012-03-02 |
2016-09-07 |
Dr. Reddy's Laboratories Ltd. |
Pharmazeutische zusammensetzungen mit borsäureverbindungen
|
CA2866590A1
(en)
|
2012-03-07 |
2013-09-12 |
Janssen Biotech, Inc. |
Defined media for expansion and maintenance of pluripotent stem cells
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
AU2013263043B2
(en)
|
2012-05-16 |
2016-06-16 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
EP2859091B1
(de)
|
2012-06-08 |
2018-08-29 |
Janssen Biotech, Inc. |
Differenzierung humaner embryonaler stammzellen in endokrine pankreaszellen
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
JP2015524394A
(ja)
|
2012-07-09 |
2015-08-24 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
US9505787B2
(en)
*
|
2012-09-11 |
2016-11-29 |
Cipla Limited |
Process for preparing of bortezomib
|
US10662477B2
(en)
|
2012-10-01 |
2020-05-26 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
WO2014076713A2
(en)
|
2012-11-16 |
2014-05-22 |
Shilpa Medicare Limited |
Crystalline bortezomib process
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
MX2015008619A
(es)
|
2012-12-31 |
2016-01-12 |
Janssen Biotech Inc |
Suspension y agrupamiento de celulas humanas pluripotentes para la diferenciacion a celulas endocrinas pancreaticas.
|
WO2014105543A1
(en)
|
2012-12-31 |
2014-07-03 |
Janssen Biotech, Inc. |
Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
|
RU2684215C2
(ru)
|
2012-12-31 |
2019-04-04 |
Янссен Байотек, Инк. |
Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
RU2737434C2
(ru)
|
2013-03-13 |
2020-11-30 |
Форма Терапьютикс, Инк. |
Новые соединения и композиции для ингибирования fasn
|
IN2013MU01431A
(de)
|
2013-04-16 |
2015-06-26 |
Cipla Ltd |
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
BR112016007237A2
(pt)
|
2013-10-03 |
2017-09-12 |
Millennium Pharm Inc |
método para a profilaxia ou tratamento do lúpus eritematoso sistêmico e/ou nefrite lúpica
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
WO2015076359A1
(ja)
*
|
2013-11-21 |
2015-05-28 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3077823B1
(de)
|
2013-12-05 |
2019-09-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation und behandlung von kachexie oder prä-kachexie
|
RU2680246C1
(ru)
|
2013-12-06 |
2019-02-19 |
Новартис Аг |
Схема приема для селективного по альфа-изоформе ингибитора фосфатидилинозитол-3-киназы
|
EP3102585B1
(de)
|
2014-02-03 |
2021-05-19 |
Ohio State Innovation Foundation |
Boronsäureester und pharmazeutische formulierungen daraus
|
EP2910557A1
(de)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiomerenreine tetrasubstituierte Pyrrolidine als Gerüste für Proteasomhemmer und medizinische Anwendungen davon
|
JP6566936B2
(ja)
|
2014-05-08 |
2019-08-28 |
国立大学法人 東京大学 |
医薬組成物
|
JP6588969B2
(ja)
|
2014-05-16 |
2019-10-09 |
ヤンセン バイオテツク,インコーポレーテツド |
膵内分泌細胞内のmafa発現を強化するための小分子の使用
|
MX2016015267A
(es)
|
2014-05-20 |
2017-02-22 |
Millennium Pharm Inc |
Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria.
|
EP3177292B1
(de)
|
2014-08-07 |
2020-11-25 |
Mayo Foundation for Medical Education and Research |
Verbindungen und verwendung zur behandlung von krebs
|
CN107074885B
(zh)
*
|
2014-10-01 |
2020-11-27 |
默克专利股份公司 |
硼酸衍生物
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
EP3270891A1
(de)
|
2015-03-17 |
2018-01-24 |
Leon-Nanodrugs GmbH |
Nanopartikel mit einer stabilisierten boronsäureverbindung
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
WO2016205790A2
(en)
|
2015-06-19 |
2016-12-22 |
Hanlin Scientific, Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
JP2018532750A
(ja)
|
2015-11-02 |
2018-11-08 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
US11111296B2
(en)
|
2015-12-14 |
2021-09-07 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiac dysfunction
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
EP3472151A4
(de)
|
2016-06-21 |
2020-03-04 |
Orion Ophthalmology LLC |
Carbocyclische prolinamidderivate
|
WO2017222915A1
(en)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Heterocyclic prolinamide derivatives
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018073790A1
(en)
|
2016-10-20 |
2018-04-26 |
Pfizer Inc. |
Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
KR20190127681A
(ko)
|
2017-02-17 |
2019-11-13 |
프레세니어스 카비 온콜로지 리미티드 |
붕소산 에스테르의 개선된 제조방법
|
WO2018160717A1
(en)
|
2017-02-28 |
2018-09-07 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
JP7289828B2
(ja)
|
2017-08-23 |
2023-06-12 |
ケザール ライフ サイエンシズ |
自己免疫疾患の治療における免疫プロテアソーム阻害剤および免疫抑制剤
|
EP3694878A1
(de)
|
2017-09-14 |
2020-08-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlung für krebs
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2019099576A1
(en)
*
|
2017-11-16 |
2019-05-23 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
SG11202003867SA
(en)
|
2017-11-16 |
2020-05-28 |
Principia Biopharma Inc |
Immunoproteasome inhibitors
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
WO2019139921A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
TW202003553A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療癌症之abbv-621與抗癌劑之組合
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
WO2020092395A1
(en)
|
2018-10-29 |
2020-05-07 |
Forma Therapeutics, Inc. |
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
JP2023553011A
(ja)
*
|
2020-12-02 |
2023-12-20 |
ホフマン・テクノロジーズ・エルエルシー |
非ヒト哺乳動物においてがんを調節するための組成物および方法
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US20230062279A1
(en)
|
2021-08-12 |
2023-03-02 |
Extrovis Ag |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|